PPT-Lenacapavir with bNAbs

Teropavimab GS5423 and Zinlirvimab GS2872 Dosed Every 6 Months in People with HIV 1 UNC Chapel Hill NC 2 University of California San Diego San Diego CA 3 CrofootMD Clinic and Research Center Houston TX . n. eutralizing . a. ntibodies: learning lessons from infections. Penny Moore. National Institute for Communicable Diseases, a division of the . National Health Laboratory Service of South Africa, . . “. Towards an HIV Cure. ”. symposium. Melbourne . Potent and Broadly Anti-HIV-1 Neutralizing Antibodies Inhibit HIV-1 Transmission from . Plasmacytoid. . Dendritic. Cells to . CD4 T Lymphocytes. Prof Lynn Morris. National Institute for Communicable Diseases, a division of the . National Health Laboratory Service . (NHLS) of . South Africa, . . University of the Witwatersrand, Johannesburg, South . Last Updated: December 28, 2022. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Subcutaneous . Lenacapavir. Administer as Subcutaneous Injection. Take with or without food. Oral . Lenacapavir. Lenacapavir. Innovation. University of the Witwatersrand, Johannesburg, South Africa. . AIDS 2022, Montreal, Canada. July/August 2022. Broadly neutralizing antibodies for HIV prevention . Outline. Proof-of-concept – the AMP trial. CAPELLA. Lenacapavir. in Multidrug Resistant HIV. CAPELLA Study: Background. Source: Segal-Maurer S, et al. N . Engl. J Med. 2022;386:1793-1803. . Background. Phase 3, randomized, trial with oral and subcutaneous . Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection. . Sallie . Permar. , MD, PhD. Nancy C . Paduano. Professor and Chair of Pediatrics, Weill Cornell Medicine. Pediatrician in Chief. Age (. yrs. ). 0. 1. 2. 3. 17. 12. 13. 14. 15. 16. 19-24. 18. HIV-1 prevalence (%).